Restoring mitochondrial quantity and quality to reverse the Warburg effect and drive neuroblastoma differentiation
Abstract
Reduced mitochondrial quality and quantity in tumors is associated with dedifferentiation and increased malignancy. However, it remains unclear how to restore mitochondrial quantity and quality in tumors and whether mitochondrial restoration can drive tumor differentiation. Our study shows that restoring mitochondrial function using retinoic acid (RA) to boost mitochondrial biogenesis and a mitochondrial uncoupler to enhance respiration synergistically drives neuroblastoma differentiation and inhibits proliferation. U- 13 C-glucose/glutamine isotope tracing revealed a metabolic shift from the pentose phosphate pathway to oxidative phosphorylation, accelerating the tricarboxylic acid cycle and switching substrate preference from glutamine to glucose. These effects were abolished by electron transport chain (ETC) inhibitors or in ρ 0 cells lacking mitochondrial DNA, emphasizing the necessity of mitochondrial function for differentiation. Dietary RA and uncoupler treatment promoted tumor differentiation in an orthotopic neuroblastoma xenograft model, evidenced by neuropil production and Schwann cell recruitment. Single-cell RNA sequencing of xenografts revealed that this strategy effectively eliminated the stem cell population, promoted differentiation, and increased mitochondrial gene signatures along the differentiation trajectory, potentially improving patient outcomes. Collectively, our findings establish a mitochondria-centric therapeutic strategy for inducing tumor differentiation, suggesting that maintaining/driving differentiation in tumor requires not only ATP production but also continuous ATP consumption and sustained ETC activity.
Article Details
Journal Info
Proceedings of the National Academy of Sciences
National Academy of Sciences
Authors (26)
Haowen Jiang
Department of Radiation Oncology, Stanford University
Sarah Jane Tiche
Department of Surgery, Stanford University
Clifford Jiajun He
Department of Radiation Oncology, Stanford University
Junyan Liu
Department of Radiation Oncology, Stanford University
Fuyun Bian
Department of Ophthalmology, Stanford University
Mohamed Jedoui
Department of Radiation Oncology, Stanford University
Balint Forgo
Department of Pathology, Stanford University
Md Tauhidul Islam
Department of Radiation Oncology, Stanford University
Meng Zhao
Pamela Emengo
Bo He
Yang Li
Albert M. Li
Department of Radiation Oncology, Stanford University
Anh T. Truong
Agilent Technologies
Jestine Ho
Agilent Technologies
Cathyrin Simmermaker
Agilent Technologies
Yanan Yang
Agilent Technologies
Meng-Ning Zhou
Department of Radiation Oncology, Stanford University
Zhen Hu
Department of Chemistry, McGill University, 801 Sherbrooke Street West, Montreal, Quebec H3A 0B8, Canada
Katrin J. Svensson
Daniel J. Cuthbertson
Agilent Technologies
Florette K. Hazard
Department of Pathology, Stanford University
Lei Xing
Department of Radiation Oncology, Stanford University
Hiroyuki Shimada
Department of Pathology, Stanford University
Bill Chiu
Department of Surgery, Stanford University
Jiangbin Ye
Department of Radiation Oncology, Stanford University